Newly available over-the-counter hearing aids offer many benefits, but consumers should be aware of the potential drawbacks
Pixels are not people: mental health apps are increasingly popular but human connection is still key
The new products emit 95 percent less harmful substances than a normal cigarette because they heat tobacco instead of burning it.
The warning comes amid a rise in demand for herbal toothpaste, particularly those that don‘t contain fluoride.
Can gaming 'addiction' lead to depression or aggression in young people? Here’s what the evidence says
Philips warned that sound-dampening foam in the continuous positive airway pressure machines, or CPAP machines, can break down over time.
People in hygiene poverty were most likely to go without shaving products, deodorant, washing powder, and other cleaning products.
The piping-hot Oishi Mizu Tennensui Sayu bottles are simply filled with the same mineral water that Asahi usually sells at cold or room temperature.
How monkeypox epidemic is likely to play out – in four graphs
The first case of monkeypox in a human was reported in 1970 in the Democratic Republic of the Congo. Since then, there have been many monkeypox outbreaks, but they have been self-limiting, with chains of human transmission ending without establishing epidemics. The current outbreak, however, is different. There is more human-to-human transmission, and it is over a much broader geographical area.
There are huge gaps in what we know about monkeypox, but combining what we do know with a history of other infectious diseases makes it possible to analyse likely future scenarios.
The four scenarios below are based on the following knowledge: the average number of people an infected person is likely to infect (assuming they have not been vaccinated against the virus or have had the disease before) is 2.13. This is called the basic reproduction number, or R. Herd immunity – the point at which enough people have immunity such that disease transmission can’t be sustained – is 53% (corresponding to this value of R). And the incubation period, the time from catching the virus to the appearance of symptoms, is between five and 21 days.
Scenario 1: Self-limiting outbreak
Plot illustrating the daily number of cases under scenario 1. The size and duration of the outbreak here and in the graphs below are for illustration purposes only and do not constitute a detailed prediction of what might happen in the future. More details available at https://statisticallyinsignificant.blog/monkeypox-scenario-modelling/ Adam Kleczkowski
In this scenario, the outbreak ends quickly once the population at risk becomes immune and herd immunity is reached locally. In the past, many people had some immunity (called “cross-immunity”) from the smallpox mass vaccination programmes of the late 20th century. So the effective reproduction number, R, can be close to or even lower than one, and the transmission will soon stop.
Behavioural changes can reduce the number R even more. For example, the ring vaccination can form a “firebreak”, further reducing the susceptible population. Similar previous epidemics include the Sars outbreak in 2002-04, when a quick intervention stopped the disease from spreading.
Scenario 2: All population
The continuing spread of monkeypox in May and June 2022 suggests that the virus is moving beyond the original network.
The size of the outbreak is already well beyond the most prominent 2017-19 outbreak in the Democratic Republic of Congo (760). It is possible that large gatherings, including raves and festivals, have created new transmission clusters.
A plot illustrating the daily number of cases under Scenario 2. Adam Kleczkowski
Scenario 2 assumes that everybody below the age of 50 is susceptible to the infection, reflecting the end of compulsory smallpox vaccination in the 1970-80s. The virus will continue spreading, effectively searching for pockets of high-risk and non-immune communities.
Unless a combination of contact tracing and ring vaccination stops the spread, the monkeypox will continue spreading. But, given the low transmissibility of monkeypox, the epidemic may fizzle out before reaching the herd immunity threshold of 50% of the population.
Scenario 3: Becoming endemic
Complete eradication is impossible because monkeypox exists in a wide range of animal hosts. The low transmissibility also means it can survive at low levels in the population. In addition, the long incubation period and variable symptoms allow it to avoid detection. Therefore, monkeypox may have already been spreading for a long time.
A plot illustrating the daily number of cases under Scenario 3. Details available at https://statisticallyinsignificant.blog/monkeypox-scenario-modelling/ Adam Kleczkowski
The influx of susceptible people through birth or migration will keep the virus in the population. Mass vaccination programmes might be needed to eradicate the disease. But relatively low monkeypox transmissibility means such programmes are likely to be highly effective.
Scenario 4: Recurrent large epidemics
The current epidemic might be the first instance of a series of outbreaks. In the long term (scenario 4), we should expect a return of monkeypox caused by future “zoonotic events” where the disease jumps from animal hosts to humans. As the cross-immunity from smallpox vaccines wanes, the epidemics can become even more substantial.
A plot illustrating the daily number of cases under Scenario 4. Details available at https://statisticallyinsignificant.blog/monkeypox-scenario-modelling/ Adam Kleczkowski
Little is known about the potential of monkeypox to mutate. Still, there is potential for it to evolve into a more rapidly spreading variant.
Effective vaccines for monkeypox exist and are about 85% effective. Although there are currently not enough doses to vaccinate everyone, there is no need for a mass-vaccination programme given monkeypox’s low transmissibility. Instead, vaccines should be offered to those most at risk, including communities in Africa most in contact with the wild animals that carry the virus.
Adam Kleczkowski receives funding from the UK Research and Innovation and the Scottish Government.